Acurx Pharmaceuticals LLC Net Income
| ACXP Stock | USD 2.28 0.10 4.20% |
As of the 4th of February, Acurx Pharmaceuticals shows the Risk Adjusted Performance of (0.11), mean deviation of 4.46, and Standard Deviation of 7.05. Acurx Pharmaceuticals LLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Acurx Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Acurx Pharmaceuticals' valuation are summarized below:There are currently ninety fundamental signals for Acurx Pharmaceuticals LLC that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Acurx Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -12.7 M | -13.3 M | |
| Net Loss | -10.9 M | -11.4 M | |
| Net Loss | -12.7 M | -13.3 M | |
| Net Loss | (19.05) | (20.00) |
Acurx | Net Income | Build AI portfolio with Acurx Stock |
Evaluating Acurx Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Acurx Pharmaceuticals LLC's fundamental strength.
Latest Acurx Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Acurx Pharmaceuticals LLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Acurx Pharmaceuticals LLC financial statement analysis. It represents the amount of money remaining after all of Acurx Pharmaceuticals LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Acurx Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acurx Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.1 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Acurx Net Income Regression Statistics
| Arithmetic Mean | (8,434,567) | |
| Coefficient Of Variation | (44.04) | |
| Mean Deviation | 3,396,196 | |
| Median | (5,931,253) | |
| Standard Deviation | 3,714,243 | |
| Sample Variance | 13.8T | |
| Range | 10M | |
| R-Value | (0.80) | |
| Mean Square Error | 5.2T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (590,680) | |
| Total Sum of Squares | 220.7T |
Acurx Net Income History
Other Fundumenentals of Acurx Pharmaceuticals LLC
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Acurx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Acurx Pharmaceuticals is extremely important. It helps to project a fair market value of Acurx Stock properly, considering its historical fundamentals such as Net Income. Since Acurx Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acurx Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acurx Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Acurx have expansion opportunities? Factors like these will boost the valuation of Acurx Pharmaceuticals. If investors know Acurx will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Acurx Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Acurx Pharmaceuticals LLC is measured differently than its book value, which is the value of Acurx that is recorded on the company's balance sheet. Investors also form their own opinion of Acurx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acurx Pharmaceuticals' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Acurx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acurx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Acurx Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acurx Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Acurx Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Acurx Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acurx Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acurx Pharmaceuticals.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Acurx Pharmaceuticals on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Acurx Pharmaceuticals LLC or generate 0.0% return on investment in Acurx Pharmaceuticals over 90 days. Acurx Pharmaceuticals is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infecti... More
Acurx Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acurx Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acurx Pharmaceuticals LLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 49.19 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 10.84 |
Acurx Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acurx Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acurx Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Acurx Pharmaceuticals historical prices to predict the future Acurx Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.24) | |||
| Total Risk Alpha | (1.57) | |||
| Treynor Ratio | (0.61) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acurx Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acurx Pharmaceuticals February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.60) | |||
| Mean Deviation | 4.46 | |||
| Coefficient Of Variation | (613.12) | |||
| Standard Deviation | 7.05 | |||
| Variance | 49.76 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.24) | |||
| Total Risk Alpha | (1.57) | |||
| Treynor Ratio | (0.61) | |||
| Maximum Drawdown | 49.19 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 10.84 | |||
| Skewness | 2.82 | |||
| Kurtosis | 13.8 |
Acurx Pharmaceuticals LLC Backtested Returns
Acurx Pharmaceuticals LLC secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15 % return per unit of risk over the last 3 months. Acurx Pharmaceuticals LLC exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Acurx Pharmaceuticals' Mean Deviation of 4.46, risk adjusted performance of (0.11), and Standard Deviation of 7.05 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.9, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acurx Pharmaceuticals will likely underperform. At this point, Acurx Pharmaceuticals LLC has a negative expected return of -1.05%. Please make sure to confirm Acurx Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and period momentum indicator , to decide if Acurx Pharmaceuticals LLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.69 |
Good predictability
Acurx Pharmaceuticals LLC has good predictability. Overlapping area represents the amount of predictability between Acurx Pharmaceuticals time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acurx Pharmaceuticals LLC price movement. The serial correlation of 0.69 indicates that around 69.0% of current Acurx Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 0.1 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Acurx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Acurx Pharmaceuticals LLC reported net income of (14.1 Million). This is 104.13% lower than that of the Biotechnology sector and 120.13% lower than that of the Health Care industry. The net income for all United States stocks is 102.47% higher than that of the company.
Acurx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acurx Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics of similar companies.Acurx Pharmaceuticals is currently under evaluation in net income category among its peers.
Acurx Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acurx Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acurx Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Acurx Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acurx Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Acurx Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acurx Pharmaceuticals' value.| Shares | State Street Corp | 2025-06-30 | 43.5 K | Ubs Group Ag | 2025-06-30 | 38.8 K | Nbc Securities Inc | 2025-06-30 | 30 K | Jane Street Group Llc | 2025-06-30 | 28 K | Northern Trust Corp | 2025-06-30 | 27.3 K | Gps Wealth Strategies Group, Llc | 2025-06-30 | 23.5 K | Baader Bank Inc | 2025-06-30 | 16.4 K | Group One Trading, Lp | 2025-06-30 | 13.6 K | Wealthcare Advisory Partners Llc | 2025-06-30 | 11.5 K | Armistice Capital, Llc | 2025-06-30 | 1.1 M | Prospect Financial Services Llc | 2025-06-30 | 296.8 K |
Acurx Fundamentals
| Return On Equity | -2.91 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | (48.26 K) | ||||
| Shares Outstanding | 2.35 M | ||||
| Shares Owned By Insiders | 6.16 % | ||||
| Shares Owned By Institutions | 8.21 % | ||||
| Number Of Shares Shorted | 79.73 K | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (14.1 M) | ||||
| Net Income | (14.1 M) | ||||
| Cash And Equivalents | 9.09 M | ||||
| Cash Per Share | 0.80 X | ||||
| Total Debt | 3.24 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 19.43 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (10.38 M) | ||||
| Short Ratio | 1.40 X | ||||
| Earnings Per Share | (8.18) X | ||||
| Target Price | 61.7 | ||||
| Beta | -1.22 | ||||
| Market Capitalization | 5.59 M | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (67.32 M) | ||||
| Working Capital | 615.12 K | ||||
| Net Asset | 3.86 M |
About Acurx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acurx Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acurx Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Acurx Stock
Moving against Acurx Stock
| 0.83 | DSGN | Design Therapeutics | PairCorr |
| 0.79 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.69 | ENGN | enGene Holdings Common | PairCorr |
| 0.67 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.65 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.